ReviewDermatology and therapy2019
Propionibacterium (Cutibacterium) acnes Bacteriophage Therapy in Acne: Current Evidence and Future Perspectives.
Review in Dermatology and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 95 citations in OpenAlex.
- Phage-Derived Endolysins TargetingAntibiotics (Basel, Switzerland) · 2026Review
- Ferrous lactate-loaded hydrogels induce iron-dependent non-canonical ferroptosis inMaterials today. Bio · 2026Article
- A Global Delphi Consensus on Acne and the Microbiome: Integrating International Expertise for Innovative Prevention and Therapeutic Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Pseudolysogeny-mediated evolutionary trade-offs favor phage therapy by limiting antibiotic resistance and virulence in Cutibacterium acnes.Scientific reports · 2026Article
- Isolation and Genomic Characterization of Two LyticViruses · 2026Article
- A comprehensive reference catalog of human skin DNA virome reveals novel viral diversity and microenvironmental influences.Microbiology spectrum · 2025Article
- Microbiota-Host Interactions: Exploring Their Dynamics and Contributions to Human Diseases.MicrobiologyOpen · 2025Review
- Discovery of antimicrobial peptides with notable antibacterial potency by an LLM-based foundation model.Science advances · 2025Article
- Antibacterial activity and impact on keratinocyte cell growth ofCurrent research in microbial sciences · 2025Article
- Cutibacterium acnes bacteriophage therapy: exploring a new frontier in acne vulgaris treatment.Archives of dermatological research · 2024Review
- Article
- Plant Phenolics in the Prevention and Therapy of Acne: A Comprehensive Review.Molecules (Basel, Switzerland) · 2024Review
- Bioadhesive Polymeric Films Containing Rhamnolipids, An Innovative Antimicrobial Topical Formulation.AAPS PharmSciTech · 2024Article
- Unveiling the Nuances of Adult Female Acne: A Comprehensive Exploration of Epidemiology, Treatment Modalities, Dermocosmetics, and the Menopausal Influence.International journal of women's health · 2024Review
- InvestigatingFrontiers in microbiology · 2024Article
- Expression of a recombinant endolysin from bacteriophage CAP 10-3 with lytic activity against Cutibacterium acnes.Scientific reports · 2023Article
- Article
- Bacteriophage therapy as an alternative technique for treatment of multidrug-resistant bacteria causing diabetic foot infection.International microbiology : the official journal of the Spanish Society for Microbiology · 2023Article
- The persistence and stabilization of auxiliary genes in the human skin virome.Virology journal · 2023Article
- The dynamic balance of the skin microbiome across the lifespan.Biochemical Society transactions · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne vulgaris is the most common dermatological disorder worldwide. It is a multifactorial disease that involves increased sebum production, hyperkeratinization of the pilosebaceous unit, Propionibacterium acnes (Cutibacterium acnes) colonization, and inflammation. The human skin microbiome hosts a wide variety of microorganisms, including bacteria, viruses, and fungi. A delicate balance of these microorganisms is essential for the barrier function of the skin. Propionibacterium acnes represents nearly 90% of the human skin microbiome of healthy adults. Acne is a chronic recurrent disease that requires long-lasting treatment, which has led to the emergence of antibiotic resistance. New alternatives to traditional therapy are emerging, including antimicrobial peptides, natural engineered antibodies, and bacteriophages. Bacteriophages have been shown to play a role in human skin health and disease. There is evidence supporting phage therapy in many types of skin infections. P. acnes bacteriophages have been isolated and characterized. However, only a few in vitro studies have tested the ability of bacteriophages to kill P. acnes. Furthermore, there is no evidence on bacteriophage therapy in the treatment of acne in humans. In this review, we summarize the most recent evidence regarding P. acnes bacteriophages and the potential role of these bacteriophages in the treatment of acne. Further research on this field will provide the evidence to use phage therapy to decrease rates of antibiotic resistance and restore antibiotic susceptibility of P. acnes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.